KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD

Matthew van Norman; Donald A Molony

doi:10.7326/J23-0023

KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD

Ann Intern Med. 2023 May;176(5):JC50. doi: 10.7326/J23-0023. Epub 2023 May 2.

Authors

Matthew van Norman¹, Donald A Molony¹

Affiliation

¹ McGovern Medical School, University of Texas, Houston, Texas, USA (M.V., D.A.M.).

PMID: 37126811
DOI: 10.7326/J23-0023

Abstract

Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176:381-387. 36623286.

Publication types

Comment

MeSH terms

Diabetes Mellitus* / drug therapy
Humans
Mineralocorticoid Receptor Antagonists
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
ras Proteins

Substances

ras Proteins
Sodium-Glucose Transporter 2 Inhibitors
Mineralocorticoid Receptor Antagonists